To avoid competing with Britain and Europe, Japan made 90 million Oxford vaccines

To avoid competing with Britain and Europe, Japan made 90 million Oxford vaccines

Japan practiced the vaccination process of new crown vaccine. Pembo

The first production place outside the United States, Europe and India

The recent spat between the European Union, the United Kingdom and AstraZeneca pharmaceutical companies over the supply of new vaccines has drawn attention from all walks of life to how to ensure the stable supply of vaccines in the case of limited or even single sources of vaccines in the world. The Japanese government confirmed yesterday that up to 90 million doses of the 120 million doses of new crown vaccine ordered from AstraZeneca will be produced locally in Japan. Sanofi, a French pharmaceutical company that originally developed new crown vaccine, also announced the day before yesterday that it will produce the vaccine of Pfizer biontech in its plant to increase the supply in Europe.

Excluding the vaccines developed and produced by China and Russia, at present, three new vaccines are mainly used in the world, namely Moderna vaccine, Oxford University and AstraZeneca vaccine, and Pfizer and biontech vaccine. The main factories of the three vaccines are located in the United States and Europe, and the only authorized non European and American manufacturer is the world’s largest vaccine in India Therefore, it is symbolic that Japan is allowed to produce its own AstraZeneca vaccine.

No relevant experience of stock solution manufacturer

Japanese media reported that Japan’s AstraZeneca vaccine stock solution will be manufactured by JCR Pharma Company in Hyogo Prefecture, and the stock solution produced will be handed over to pharmaceutical company “first Sankyo” in Tokyo and pharmaceutical company km biology in Kumamoto.

AstraZeneca vaccine belongs to & quot; adenovirus vector vaccine wpap63005qte, that is, the genetic information of new coronavirus is implanted into the adenovirus causing cold, and then transmitted to the body to promote the immune response. The report pointed out that although JCR Pharma had no experience in vaccine production in the past, the company was able to start the vaccine production line in a short time due to its biotechnology such as cell culture, the ability to cultivate adenovirus used to extract vaccine stock solution, and the acquisition of AstraZeneca’s production technology and the provision of gene modified adenovirus.

AstraZeneca to apply for Japanese license

It is reported that AstraZeneca will apply to Japan for an emergency use license in the near future, and plans to supply 60 million doses of vaccines produced overseas to Japan by the end of March, while the rest will be left to Japan for local production. Japan has also signed contracts with Pfizer and Moderna to buy vaccines, but as both vaccines need to be stored in low temperature, the AstraZeneca vaccine is regarded as the key to expand vaccination before the Olympic Games.

On the other hand, Sanofi, which originally developed its own vaccine, announced the day before yesterday that it agreed to use its factory in Frankfurt, Germany, to produce 125 million doses of Xinguan vaccine on behalf of Pfizer. This is a rare cooperative move in the pharmaceutical industry, which has always been highly competitive. A Sanofi spokesman said that after the new candidate vaccine developed on the basis of influenza vaccine proved that it could not produce the expected immune effect in December last year, the company began to think about how to cooperate with other competitors and described it as Pfizer OEM, showing the unity of the pharmaceutical industry, which they were “proud of”;.


您的电子邮箱地址不会被公开。 必填项已用*标注